Electra Therapeutics (ETRA) vs Monopar Therapeutics (MNPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Electra Therapeutics is the larger company by market cap ($569.9 million vs $559.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETRA | MNPR |
|---|---|---|
| Share price | $9.08 | $83.42 |
| Market cap | $569.92M | $559.93M |
| 1-day change | -0.87% | -0.43% |
| YTD return | — | +28.30% |
| 1-year return | — | -14.96% |
| 5-year return | — | +241.26% |
| EPS (TTM) | $-2.65 | $-2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.50 | $124.82 |
| 52-week low | $8.63 | $50.07 |
| Distance from 52-week high | -41.42% | -33.17% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +55.74% |
| Average volume | 948.89K | 215.52K |
| Shares outstanding | 62.77M | 6.71M |
| Employees | 46 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Electra Therapeutics
ETRA stock →Electra Therapeutics, Inc. is a clinical-stage biotechnology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
ETRA vs MNPR FAQ
Which is bigger, Electra Therapeutics or Monopar Therapeutics?
Electra Therapeutics (ETRA) is larger, with a market capitalization of $569.92M compared with $559.93M for Monopar Therapeutics (MNPR).
Are Electra Therapeutics and Monopar Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Electra Therapeutics and Biotechnology: Pharmaceutical Preparations for Monopar Therapeutics.